Want to see GB:FAB full AI Analyst Report?
Top Page
Fusion Antibodies Plc
(LSE:FAB)
Select Model
Select Model
Rating:43Neutral
Price Target:
5.50 p
â–¼(-51.11% Downside)
Action:Reiterated
Date:10/16/26
The score is primarily weighed down by weak financial performance (large ongoing losses and continued cash burn) and bearish technicals (price below all major moving averages with negative momentum). Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Revenue rebound
The strong 2026 revenue rebound indicates that customer demand and project activity can recover materially after a weaker period. If this improvement persists, greater scale could support better utilization, strengthen the company’s position in antibody services, and provide a foundation for future operating leverage.
Negative Factors
Persistent operating losses
Very negative operating and net margins show that the current revenue base is not yet sufficient to cover the company’s cost structure. Continued losses reduce financial resilience, make earnings dependent on future growth or funding, and indicate that sustainable profitability remains an unresolved fundamental challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The strong 2026 revenue rebound indicates that customer demand and project activity can recover materially after a weaker period. If this improvement persists, greater scale could support better utilization, strengthen the company’s position in antibody services, and provide a foundation for future operating leverage.
Read all positive factors
Fusion Antibodies Plc (FAB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.88M
Dividend YieldN/A
Average Volume (3M)727.19K
Price to Earnings (P/E)―
Beta (1Y)-0.63
Revenue Growth7.38%
EPS Growth44.13%
CountryUK
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,156,876
10 Day Avg. Volume1,251,187
30 Day Avg. Volume727,187
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)8.89
Price to Sales (P/S)6.83
P/FCF Ratio-12.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.10M
Fusion Antibodies Plc Business Overview & Revenue Model
Company Description
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncolog...
How the Company Makes Money
Fusion Antibodies makes money primarily by selling fee-for-service R&D and development work to external customers on a project basis. Key revenue streams typically include: (1) Contract antibody discovery and generation work, where clients pay for...
Fusion Antibodies Plc Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
26
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.11M | 1.97M | 1.14M | 2.90M | 4.80M |
| Gross Profit | 1.10M | 430.00K | -265.00K | 202.00K | 1.72M |
| EBITDA | -1.85M | -1.62M | -2.06M | -2.48M | -573.00K |
| Net Income | -1.15M | -1.71M | -2.23M | -2.60M | -1.20M |
Balance Sheet | |||||
| Total Assets | 2.73M | 1.32M | 2.42M | 2.06M | 4.92M |
| Cash, Cash Equivalents and Short-Term Investments | 1.04M | 359.00K | 1.20M | 195.00K | 2.05M |
| Total Debt | 331.00K | 20.00K | 43.00K | 75.00K | 69.00K |
| Total Liabilities | 1.10M | 654.00K | 627.00K | 939.00K | 1.23M |
| Stockholders Equity | 1.62M | 669.00K | 1.79M | 1.12M | 3.68M |
Cash Flow | |||||
| Free Cash Flow | -1.17M | -1.37M | -1.77M | -1.87M | -591.00K |
| Operating Cash Flow | -1.11M | -1.36M | -1.77M | -1.75M | -333.00K |
| Investing Cash Flow | -60.00K | -5.00K | 1.00K | -114.00K | -258.00K |
| Financing Cash Flow | 1.85M | 529.00K | 2.77M | 7.00K | -46.00K |
Fusion Antibodies Plc Technical Analysis
Negative
11.25
Price Trends
10.10
Negative
10.61
Negative
12.11
Negative
Market Momentum
-1.51
Positive
20.21
Positive
19.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FAB, the sentiment is Negative. The current price of 11.25 is above the 20-day moving average (MA) of 8.38, above the 50-day MA of 10.10, and below the 200-day MA of 12.11, indicating a bearish trend. The MACD of -1.51 indicates Positive momentum. The RSI at 20.21 is Positive, neither overbought nor oversold. The STOCH value of 19.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FAB.
Fusion Antibodies Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
89 Outperform | £103.97M | 14.01 | 65.83% | 7.54% | -1.10% | 0.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £299.37M | -6.74 | -1293.07% | ― | ― | ― | |
44 Neutral | £107.89M | -5.09 | 128.87% | ― | -100.00% | -30.39% | |
43 Neutral | £6.88M | -5.56 | -97.87% | ― | 7.38% | 44.13% | |
43 Neutral | £10.92M | -10.50 | -46.61% | ― | 28.35% | 57.14% | |
42 Neutral | £10.85M | -8.30 | 609.63% | ― | ― | 56.00% |
* Healthcare Sector Average
GB:FAB
Fusion Antibodies Plc
5.50
-7.75
-58.49%
GB:AVCT
Avacta Group plc
61.50
-7.00
-10.22%
GB:BVXP
Bioventix
1,990.00
287.74
16.90%
GB:SCLP
Scancell Holdings
89.00
-7.50
-7.77%
GB:GENF
Genflow Biosciences Plc
1.83
-0.18
-8.75%
GB:APTA
Aptamer Group Plc
0.32
-0.53
-62.94%
Fusion Antibodies Plc Corporate Events
Business Operations and Strategy
Fusion Antibodies wins complex antibody project from major pharma client
Positive
Oct 22, 2026
Fusion Antibodies plc has secured a new contract from a US-based specialty division of a global pharmaceutical company to deliver transient gene expression of the client’s lead antibody followed by a cryogenic electron microscopy study. The ...
Business Operations and StrategyFinancial Disclosures
Fusion Antibodies Wins Complex Antibody Development Contract with Global Pharma Client
Positive
Oct 22, 2026
Fusion Antibodies plc, a Belfast-based CRO focused on antibody engineering and pre-clinical development for therapeutic and diagnostic uses, provides end-to-end services from antibody generation and humanisation to stable cell line production. The...
Business Operations and StrategyShareholder Meetings
Fusion Antibodies AGM Resolutions Passed as Company Targets Expanding Antibody Market
Positive
Oct 15, 2026
Fusion Antibodies plc, a specialist in antibody engineering and pre-clinical discovery services for pharma and diagnostics clients, reported that all resolutions at its annual general meeting were duly passed. The Belfast-based CRO, listed on AIM,...
Business Operations and StrategyFinancial Disclosures
Fusion Antibodies Warns on H1 Trading but Flags Progress in DR5 Programme and OptiMAL Platform
Negative
Oct 15, 2026
Fusion Antibodies has reported a sharp decline in first-half trading, with unaudited H1 FY27 revenues falling to about £457,000 from £838,000 a year earlier and gross margin compressed to 10% amid difficult market conditions. Cash at 30 ...
Business Operations and StrategyProduct-Related Announcements
Fusion Antibodies launches revamped customer-focused website to showcase antibody services
Positive
Oct 5, 2026
Fusion Antibodies plc, a specialist in pre-clinical antibody discovery and engineering, has launched a redesigned customer-focused website aimed at better presenting its discovery, engineering and supply capabilities. The updated site is designed ...
Financial DisclosuresShareholder Meetings
Fusion Antibodies Publishes 2026 Annual Report and Sets AGM Date
Neutral
Sep 22, 2026
Fusion Antibodies plc, a specialist in antibody engineering and related contract research services for pharmaceutical and diagnostic companies, has built a strong track record in antibody generation and humanisation using its proprietary technolog...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Fusion Antibodies boosts margins and cash as OptiMAL launch and patents strengthen growth platform
Positive
Sep 15, 2026
Fusion Antibodies reported audited revenues of £2.1 million for the year to 31 March 2026, with underlying service revenue of £1.86 million and second-half revenue up 21% versus the first half. The company’s gross margin rose sharp...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Fusion Antibodies boosts margins and cash as OptiMAL launch and patents advance
Positive
Sep 14, 2026
Fusion Antibodies reported audited revenues of £2.1m for the year to 31 March 2026, with underlying service revenue of £1.86m and a 21% second-half uplift that helped lift gross margin to 53%. The operating loss narrowed to £1.13m d...
Business Operations and StrategyProduct-Related Announcements
Fusion Antibodies Wins Canadian Patent for OptiMAL Antibody Library
Positive
Sep 9, 2026
Fusion Antibodies plc, a Belfast-based CRO focused on antibody engineering for therapeutic and diagnostic use, provides end-to-end services spanning antibody generation, development, production, characterisation and optimisation. The AIM-traded co...
Business Operations and StrategyFinancial Disclosures
Fusion Antibodies to unveil annual results with open investor presentation
Positive
Sep 9, 2026
Fusion Antibodies Plc, a Belfast-based specialist in pre-clinical antibody discovery and engineering, operates as a contract research organisation serving therapeutic and diagnostic markets. The AIM-listed company offers end-to-end antibody genera...
Business Operations and StrategyRegulatory Filings and Compliance
Fusion Antibodies Secures Australian Acceptance for Antibody Library Patent
Positive
Aug 6, 2026
Fusion Antibodies has received a notice of acceptance from IP Australia for its Australian patent application covering an antibody library and associated design methods. The patent, once granted, is expected to enhance the company’s Opti-des...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.